Cargando…

Striatal Dopamine Release in Schizophrenia Comorbid with Substance Dependence

Dopamine plays a role in the pathophysiology of schizophrenia and addiction. Imaging studies have indicated that striatal dopamine release is increased in schizophrenia, predominantly in the precommissural caudate (preDCA), and blunted in addiction, mostly in the ventral striatum (VST). Therefore we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Judy L., Urban, Nina, Slifstein, Mark, Xu, Xiaoyan, Kegeles, Lawrence S., Girgis, Ragy R., Beckerman, Yael, Harkavy-Friedman, Jill M., Gil, Roberto, Abi-Dargham, Anissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128915/ https://www.ncbi.nlm.nih.gov/pubmed/22869037 http://dx.doi.org/10.1038/mp.2012.109

Ejemplares similares

Deficits in striatal dopamine release in cannabis dependence
por: van de Giessen, Elsmarieke, et al.
Publicado: (2016)

43.4 THE ROLE OF MOLECULAR IMAGING IN GUIDING DRUG DEVELOPMENT
por: Abi-Dargham, Anissa, et al.
Publicado: (2018)

PET imaging of dopamine-D2 receptor internalization in schizophrenia
por: Weinstein, Jodi J., et al.
Publicado: (2017)

27. THE ROLE OF DOPAMINE IN SHAPING CIRCUITRY RELATED TO SCHIZOPHRENIA AND ADDICTION
por: Abi-Dargham, Anissa
Publicado: (2018)

Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia
por: Williams, John C., et al.
Publicado: (2022)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms
por: McCutcheon, Robert A., et al.
Publicado: (2019)

Mechanisms of Working Memory Impairment in Schizophrenia
por: Van Snellenberg, Jared X., et al.
Publicado: (2016)

3.3 DISTURBANCES IN NEURAL OSCILLATIONS, GLUTAMATE, AND GABA: EFFECTS OF KETAMINE AND COMPARISON TO SCHIZOPHRENIA
por: Kegeles, Lawrence, et al.
Publicado: (2018)

Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
por: Abi-Dargham, Anissa
Publicado: (2021)

Dopamine in the history of the schizophrenic brain: recent contributions of brain-imaging studies
por: Lamelle, Marc, et al.
Publicado: (2000)

Abnormal Striatal Dopamine Transmission in Schizophrenia
por: Brunelin, Jerome, et al.
Publicado: (2013)

27.1 TRANSLATIONAL EVIDENCE OF DOPAMINE-RELATED ALTERATIONS OF BASAL GANGLIA AND THALAMO-CORTICAL NEUROCIRCUITRY IN SCHIZOPHRENIA: A FULL CLINIC-TO-BENCH-TO-CLINIC BACK-TRANSLATION
por: Van Snellenberg, Jared, et al.
Publicado: (2018)

Striatal dopamine, reward, and decision making in schizophrenia
por: Deserno, Lorenz, et al.
Publicado: (2016)

GABA level, gamma oscillation, and working memory performance in schizophrenia
por: Chen, Chi-Ming A., et al.
Publicado: (2014)

Dopamine D(1) receptors in cocaine dependence measured with PET and the choice to self-administer cocaine
por: Martinez, Diana, et al.
Publicado: (2009)

S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA
por: Kim, Seoyoung, et al.
Publicado: (2018)

Striatal Dopamine and Reward Prediction Error Signaling in Unmedicated Schizophrenia Patients
por: Katthagen, Teresa, et al.
Publicado: (2020)

Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials
por: Clark, Samuel D., et al.
Publicado: (2020)

Deep rTMS of the insula and prefrontal cortex in smokers with schizophrenia: Proof-of-concept study
por: Moeller, Scott J., et al.
Publicado: (2022)

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2017)

Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia
por: Srivastav, Sunil, et al.
Publicado: (2023)

Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons
por: Kosillo, Polina, et al.
Publicado: (2016)

Decreased striatal adenosine A(2A)-dopamine D(2) receptor heteromerization in schizophrenia
por: Valle-León, Marta, et al.
Publicado: (2020)

Local control of striatal dopamine release
por: Cachope, Roger, et al.
Publicado: (2014)

Striatal Dopamine Signals and Reward Learning
por: Bech, Pol, et al.
Publicado: (2023)

Demographic and Clinical Correlates of Substance Abuse Comorbidity in Schizophrenia
por: Aich, Tapas K., et al.
Publicado: (2004)

Substance Use Disorders in Schizophrenia—Clinical Implications of Comorbidity
por: Volkow, Nora D.
Publicado: (2009)

Morbidity and mortality in schizophrenia with comorbid substance use disorders
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

O5.1. STRIATAL DOPAMINE AND REDUCED REWARD PREDICTION ERROR SIGNALING IN UNMEDICATED SCHIZOPHRENIA PATIENTS
por: Katthagen, Teresa, et al.
Publicado: (2020)

Dopamine regulation of striatal inhibitory transmission and plasticity: dopamine, low or high?
por: Hernández-Echeagaray, Elizabeth
Publicado: (2016)

Striatal Dopamine and the Interface between Motivation and Cognition
por: Aarts, Esther, et al.
Publicado: (2011)

Endocannabinoid–Dopamine Interactions in Striatal Synaptic Plasticity
por: Mathur, Brian N., et al.
Publicado: (2012)

Characteristic response of striatal astrocytes to dopamine depletion
por: Zhu, Yao-Feng, et al.
Publicado: (2019)

Schizophrenia and substance use comorbidity: a genome-wide perspective
por: Polimanti, Renato, et al.
Publicado: (2017)

Striatal dopamine D(2/3) receptors in medication-naïve schizophrenia: an [(123)I] IBZM SPECT study
por: Chen, Kao Chin, et al.
Publicado: (2022)

Plasticity in striatal dopamine release is governed by release-independent depression and the dopamine transporter
por: Condon, Mark D., et al.
Publicado: (2019)

Dopamine–prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity
por: Gragnoli, C, et al.
Publicado: (2016)

Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden
por: Lähteenvuo, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5dqu4qu4nhq53jvavjhbp9qs34